Immunotherapy before surgery for early-stage liver cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests whether giving an immunotherapy drug called QL1706 before surgery can help lower the risk of liver cancer coming back. It is for people with early-stage liver cancer that is at higher risk of returning, and the goal is to see if this approach is safe and effective.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have early-stage liver cancer (stage IB or IIA) that can be removed with surgery and has features that make it likely to come back.
- You have not had chemotherapy, radiation, or other cancer treatments before.
- Your liver is working well enough (Child-Pugh grade A), and you can manage daily activities without help (ECOG score 0 or 1).
- You do not have autoimmune diseases like lupus or uncontrolled hepatitis B or C.
- You agree to use birth control during and for 6 months after treatment, if applicable.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two immunotherapy drugs (iparomlimab and tuvonralimab) plus bevacizumab (a drug that cuts off blood supply to the tumor) given after surgery or ablation for liver cancer. The goal is to lower the chance of cancer coming back. The treatment is given as an infusion and may help patients with certain high-risk features.
This trial tests whether giving a combination of two immunotherapy drugs before surgery can lower the chance of liver cancer coming back in people who have high-risk features. It may help patients with early-stage liver cancer that can be removed surgically.
This trial tests a combination of immunotherapy drugs, radiation therapy, and a targeted therapy drug before and after surgery for people with intermediate-stage liver cancer that can be surgically removed. The goal is to see if this approach can shrink tumors and improve outcomes.
This trial combines two immunotherapy drugs with a targeted therapy, radiation, and a liver-directed chemotherapy infusion for liver cancer that has spread to the portal vein (the main blood vessel to the liver). The goal is to see if this combination can shrink tumors and help people live longer.
This study tests whether giving a combination of two drugs—tislelizumab (an immunotherapy that helps your immune system fight cancer) and lenvatinib (a targeted therapy that blocks tumor growth)—before surgery can improve outcomes for people with early-stage liver cancer (a single tumor 2-5 cm) when the surgery is likely to have a narrow margin. You would receive the drugs for a few weeks before your scheduled surgery, and then have the surgery as planned. This approach may help reduce the chance of the cancer coming back.
This trial tests whether a combination of two drugs (tislelizumab and lenvatinib) given before surgery can lower the risk of liver cancer coming back in people with early-stage but high-risk disease.
Hear when a new Iparomlimab and Tuvonralimab Injection trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.